|Drug class||Orexin antagonist|
|Chemical and physical data|
|Molar mass||450.927 g/mol g·mol−1|
|3D model (JSmol)|
Nemorexant, now called Daridorexant (developmental code name ACT-541468) is a dual orexin receptor antagonist (DORA) which was originated by Actelion Pharmaceuticals and is under development by Idorsia Pharmaceuticals for the treatment of insomnia. It acts as a selective dual antagonist of the orexin receptors OX1 and OX2. As of June 2018, nemorexant is in phase III clinical trials for the treatment of insomnia.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|